





FIGURES 1A-B



FIGURES 2A-D




FIGURE 3

Characteristic	Controls (N=35)		Cocaine users (N=20)		p-value
	N	%	N	%	
Race/ethnicity					0.08
African American	14	40	15	75	
Caucasian	5	14	2	10	
Hispanic	4	11	3	15	
Other	7	20	0	0	
Tobacco users	13	37	15	75	0.011
Occasional alcohol use	14	82	16	84	1
Occasional cannabis use	3	18	9	47	0.08
	Mean	SD	Mean	SD	
Age (years)	45.1	10.2	47.3	8.1	0.41
Education (years)	14.3	1.8	12.4	1.29	<0.001
Perceived social support (MSPSS total)	70.9	7.5	60.6	15.2	0.014
Body mass index	26.0	3.8	27.3	2.5	0.23
Depressive symptoms (BDI total)	1.2	1.8	7.5	8.8	0.005
Cigarettes per day (tobacco users only)	8.9	5.7	5.9	2.2	0.01
Duration of cocaine use (years)	-	-	21.9	9.3	-
Money spent on cocaine* (weekly)	-	-	\$207	138	-

P-value reports results of t-tests for continuous measures and χ^2 or Fisher's tests for tests of proportions. AA=African American, C=Caucasian, H=Hispanic, O=other, MSPSS=Multidimensional Scale of Perceived Social Support, BDI=Beck Depression Inventory, average money spent per week on cocaine is used as a proxy for amount of use.
 *Cocaine cost approximately \$30/g in the New York City area at the time the data was being collected.

FIGURE 4

Demographic and clinical characteristics of the entire sample (Baseline Sample; Study 1 + Study 2), the subjects with pre- post-L-DOPA treatment scales (L-DOPA Sample; Study 2), and the subjects with pre- and post-L-DOPA treatment fMRI (Follow-up Subgroup; Study 2 subset).

Characteristic	Baseline Sample (<i>N</i> = 33; Study 1 + Study 2)	L-DOPA Sample (<i>N</i> = 15; Study 2)	Follow-up Subgroup (<i>N</i> = 6; Study 2)	<i>P</i> -value [§]
Age (years)	71.8 ± 6.5	72.7 ± 6.3	73.7 ± 5.5	0.89
Sex (female)	21 (63.6%)	9 (60%)	4 (66.7%)	0.67
Education (years)	16.8 ± 2.5	16.7 ± 2.1	16.8 ± 1.8	0.98
Race				
Asian	2 (6.1%)	1 (6.7%)	0 (0.0%)	0.40
Black	12 (36.4%)	9 (60%)	3 (50.0%)	0.52
White	17 (51.5%)	4 (26.7%)	2 (33.3%)	0.63
Other	2 (6.1%)	1 (6.7%)	1 (16.7%)	0.20
Diagnosis				
MDD	26 (78.8%)	11 (73.7%)	5 (83.3%)	0.47
Dysthymia	2 (6.1%)	1 (6.7%)	0 (0.0%)	0.40
Depression NOS	5 (15.2%)	3 (20%)	1 (16.7%)	0.79
Duration of Current Depressive Episode (weeks)	634.5 ± 977.5	582.9 ± 999.7	538.0 ± 875.5	0.81
Number of Prior Antidepressant Medications	0.9 ± 1.4	0.3 ± 0.7	0.3 ± 0.5	1.00
Baseline CGI-S	3.6 ± 0.8	3.4 ± 0.8	3.3 ± 1.0	1.00
Baseline CES-D	26.5 ± 11.3	21.7 ± 11.3	20.0 ± 8.9	0.67
Baseline HRSD	20.7 ± 6.6	17.5 ± 5.8	16.5 ± 6.9	0.84
ΔHRSD	—	-7.8 ± 7.1	-5.8 ± 10.3	0.71
Baseline Digit Symbol	36.8 ± 10.7	30.0 ± 8.8	35.8 ± 10.1	0.05
ΔDigit Symbol	—	9.6 ± 8.2	7.0 ± 5.3	0.28
Baseline Gait Speed (m/s)	0.97 ± 0.10	0.77 ± 0.19	0.77 ± 0.15	0.72
ΔGait Speed (m/s)	—	0.10 ± 0.13	0.05 ± 0.10	0.29


Values are mean ± standard deviation or *N* (%).

CGI-S Clinical Global Impressions–Severity, CES-D Center for Epidemiological Studies–Depression, HRSD


Hamilton Rating Scale for Depression, NOS not otherwise specified

[§]Comparison between subjects treated with L-DOPA with follow-up fMRI and those without follow-up fMRI


FIGURE 5



FIGURES 6A-B



FIGURES 7A-B



FIGURES 8A-C